You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLevomilnacipran
Accession NumberDB08918
TypeSmall Molecule
GroupsApproved
DescriptionLevomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor. Chemically, levomilnacipran is the 1S,2R-enantiomer of milnacipran. FDA approved on July 25, 2013.
Structure
Thumb
Synonyms
(1S,2R)-milnacipran
External Identifiers
  • F 2695
  • F-2695
  • F2695
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FetzimaCapsule, extended release20 mg/1OralAllergan Usa, Inc.2013-07-25Not applicableUs
FetzimaCapsule, extended release40 mg/1OralAvera Mc Kennan Hospital2015-03-09Not applicableUs
FetzimaCapsule, extended release120 mgOralAllergan Pharma Co.2016-04-22Not applicableCanada
FetzimaCapsule, extended release40 mg/1OralAllergan Usa, Inc.2013-07-25Not applicableUs
FetzimaCapsule, extended release20 mgOralAllergan Pharma Co.2015-11-19Not applicableCanada
FetzimaKitOralAllergan Usa, Inc.2013-07-25Not applicableUs
FetzimaCapsule, extended release80 mg/1OralAllergan Usa, Inc.2013-07-25Not applicableUs
FetzimaCapsule, extended release40 mgOralAllergan Pharma Co.2015-11-19Not applicableCanada
FetzimaCapsule, extended release120 mg/1OralAllergan Usa, Inc.2013-07-25Not applicableUs
FetzimaCapsule, extended release80 mgOralAllergan Pharma Co.2016-04-22Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Levomilnacipran hydrochloride
175131-60-9
Thumb
  • InChI Key: XNCDYJFPRPDERF-NQQJLSKUSA-N
  • Monoisotopic Mass: 282.149891075
  • Average Mass: 282.809
DBSALT000107
Categories
UNIIUGM0326TXX
CAS number96847-54-0
WeightAverage: 246.348
Monoisotopic: 246.173213336
Chemical FormulaC15H22N2O
InChI KeyGJJFMKBJSRMPLA-DZGCQCFKSA-N
InChI
InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m0/s1
IUPAC Name
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
SMILES
CCN(CC)C(=O)[C@]1(C[[email protected]]1CN)C1=CC=CC=C1
Pharmacology
IndicationLevomilnacipran is a serotonin and norepinephrine reuptake inhibitor and is indicated for the treatment of major depressive disorder (MDD).
Structured Indications
PharmacodynamicsLevomilnacipran binds with high affinity to human serotonin (5-HT) and norepinephrine (NE) transporters (Ki = 11 and 91 nM, respectively). It potently inhibits 5-HT and NE reuptake (IC50 = 16 - 19 and 11 nM, respectively). Levomilnacipran does not bind to any other receptors, ion channels, or transporters, including serotonergic (5HT1-7), α- and β adrenergic, muscarinic, or histaminergic receptors and Ca2+, Na+, K+ or Cl- channels to a significant degree. Levomilnacipran did not inhibit monoamine oxidase (MAO). Furthermore, levomilnacipran does not prolong the QTc interval to a clinically relevant extent.
Mechanism of actionThe exact mechanism of the antidepressant action of levomilnacipran is unknown but is thought to be related to the potentiation of serotonin and norephinephrine in the central nervous system through inhibition of reuptake at serotonin and norepinephrine transporters.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent serotonin transporterProteinyes
inhibitor
HumanP31645 details
Sodium-dependent noradrenaline transporterProteinyes
inhibitor
HumanP23975 details
Related Articles
AbsorptionThe relative bioavailability after administration of the extended-release capsule was 92% when compared to oral solution. Food does not affect the concentration of levomilnacipran. After daily dosing of levomilnacipran (extended-release capsule) the mean Cmax is 341 ng/mL, and the mean steady-state AUC value is 5196 ng·h/mL. The Tmax is 6 - 8 hours after oral administration. Interconversion of stereoisomers does not occur in humans.
Volume of distribution
  • 387 – 473 L [apparent volume of distribution]
Protein binding22% bound to human plasma protein over concentration range of 10 to 1000 ng/mL.
Metabolism

Hepatic. Levomilnacipran undergoes desethylation to form desethyl levomilnacipran and hydroxylation to form p-hydroxy-levomilnacipran. Desethylation is facilitated primarily by CYP3A4 and by CYP2C8, 2C19, 2D6, and 2J2 to a lesser extent. Both metabolites undergo further conjugation with glucuronide to form conjugates.

Route of eliminationLevomilnacipran and its metabolites are eliminated primarily by renal excretion. 58% of the dose is excreted in urine as unchanged levomilnacipran. N-desethyl levomilnacipran is the major metabolite excreted in the urine and accounted for approximately 18% of the dose. Other identifiable metabolites excreted in the urine are levomilnacipran glucuronide (4%), desethyl-levomilnacipran glucuronide (3%), p-hydroxy levomilnacipran glucuronide (1%), and p-hydroxylevomilnacipran (1%). The metabolites are inactive.
Half life12 hours
Clearance
  • 21 – 29 L/h [mean apparent total clearance]
ToxicityThe most common adverse reactions are nausea, constipation, hyperhidrosis, heart rate increase, erectile dysfunction, tachycardia, vomiting, and palpitations.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when 1,1,1,2 Tetrafluoroethane is combined with Levomilnacipran.Investigational
4-MethoxyamphetamineLevomilnacipran may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Levomilnacipran.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Levomilnacipran.Experimental
AbirateroneThe serum concentration of Levomilnacipran can be increased when it is combined with Abiraterone.Approved
AcarboseLevomilnacipran may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Levomilnacipran.Approved
AcenocoumarolThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Levomilnacipran.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Levomilnacipran can be increased when it is combined with Acetaminophen.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Acetophenazine.Approved
Acetylsalicylic acidLevomilnacipran may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Levomilnacipran.Investigational
AdrafinilLevomilnacipran may increase the tachycardic activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Levomilnacipran can be increased when it is combined with Afatinib.Approved
AgmatineLevomilnacipran may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Levomilnacipran.Approved, Investigational
AlbendazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Albendazole.Approved, Vet Approved
AlbiglutideLevomilnacipran may increase the hypoglycemic activities of Albiglutide.Approved
AldosteroneThe serum concentration of Levomilnacipran can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Levomilnacipran can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Levomilnacipran.Vet Approved
AlfentanilThe serum concentration of Levomilnacipran can be increased when it is combined with Alfentanil.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Levomilnacipran.Approved, Vet Approved
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Levomilnacipran.Approved, Investigational
AlogliptinLevomilnacipran may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Levomilnacipran.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levomilnacipran.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Levomilnacipran.Approved, Withdrawn
AmantadineThe serum concentration of Levomilnacipran can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Levomilnacipran can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Levomilnacipran can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Amisulpride.Approved, Investigational
AmitrazLevomilnacipran may increase the tachycardic activities of Amitraz.Vet Approved
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Levomilnacipran.Approved
AmlodipineThe serum concentration of Levomilnacipran can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levomilnacipran.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levomilnacipran.Approved
AmperozideThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Amperozide.Experimental
AmprenavirThe serum concentration of Levomilnacipran can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Levomilnacipran can be increased when it is combined with Amsacrine.Approved
AnisodamineLevomilnacipran may increase the tachycardic activities of Anisodamine.Investigational
Aop200704The serum concentration of Aop200704 can be increased when it is combined with Levomilnacipran.Investigational
ApomorphineLevomilnacipran may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineLevomilnacipran may increase the tachycardic activities of Apraclonidine.Approved
AprepitantThe serum concentration of Levomilnacipran can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineLevomilnacipran may increase the tachycardic activities of Arbutamine.Approved
ArformoterolLevomilnacipran may increase the tachycardic activities of Arformoterol.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Aripiprazole.Approved, Investigational
ArmodafinilThe metabolism of Levomilnacipran can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Levomilnacipran.Approved
ArtemetherThe metabolism of Levomilnacipran can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Levomilnacipran.Approved
AsenapineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Asenapine.Approved
AstemizoleThe serum concentration of Levomilnacipran can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Levomilnacipran can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Levomilnacipran can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Levomilnacipran can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Levomilnacipran can be increased when it is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Azaperone.Vet Approved
AzelastineThe serum concentration of Levomilnacipran can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Levomilnacipran can be increased when it is combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Levomilnacipran.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Levomilnacipran.Illicit
BefunololLevomilnacipran may increase the tachycardic activities of Befunolol.Experimental
BendroflumethiazideLevomilnacipran may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Levomilnacipran.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Benperidol.Investigational
BenzocaineThe serum concentration of Levomilnacipran can be increased when it is combined with Benzocaine.Approved
BenzphetamineLevomilnacipran may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Levomilnacipran.Approved
BepridilThe serum concentration of Levomilnacipran can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololThe metabolism of Levomilnacipran can be decreased when combined with Betaxolol.Approved
BethanidineLevomilnacipran may decrease the antihypertensive activities of Bethanidine.Approved
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Levomilnacipran.Approved
BexaroteneThe serum concentration of Levomilnacipran can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideBezitramide may increase the serotonergic activities of Levomilnacipran.Experimental, Illicit, Withdrawn
BifeprunoxThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Bifeprunox.Investigational
BiperidenThe serum concentration of Levomilnacipran can be increased when it is combined with Biperiden.Approved
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Levomilnacipran.Approved
BitolterolLevomilnacipran may increase the tachycardic activities of Bitolterol.Withdrawn
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Levomilnacipran.Investigational
BoceprevirThe serum concentration of Levomilnacipran can be increased when it is combined with Boceprevir.Approved
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Levomilnacipran.Approved
BortezomibThe metabolism of Levomilnacipran can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Levomilnacipran can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Levomilnacipran can be increased when it is combined with Bosutinib.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Brexpiprazole.Approved
BrimonidineLevomilnacipran may increase the tachycardic activities of Brimonidine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levomilnacipran.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Levomilnacipran.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Levomilnacipran.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Levomilnacipran.Approved, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Levomilnacipran.Investigational
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Levomilnacipran.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levomilnacipran.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Levomilnacipran.Approved
BuprenorphineThe serum concentration of Levomilnacipran can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Levomilnacipran can be decreased when combined with Bupropion.Approved
BuspironeBuspirone may increase the serotonergic activities of Levomilnacipran.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levomilnacipran.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Levomilnacipran.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Levomilnacipran.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Levomilnacipran.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Levomilnacipran.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Levomilnacipran.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Levomilnacipran can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Levomilnacipran.Approved
CaffeineThe serum concentration of Levomilnacipran can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Levomilnacipran can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Levomilnacipran can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Levomilnacipran can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Levomilnacipran.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levomilnacipran.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Levomilnacipran.Illicit, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levomilnacipran.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Levomilnacipran.Withdrawn
CarteololThe serum concentration of Carteolol can be increased when it is combined with Levomilnacipran.Approved
CarvedilolThe serum concentration of Levomilnacipran can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Levomilnacipran can be increased when it is combined with Caspofungin.Approved
CelecoxibLevomilnacipran may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Levomilnacipran.Approved, Investigational
CeritinibThe serum concentration of Levomilnacipran can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Levomilnacipran.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Levomilnacipran.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Levomilnacipran can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Levomilnacipran.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Levomilnacipran.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levomilnacipran.Approved
ChloroquineThe serum concentration of Levomilnacipran can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideLevomilnacipran may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levomilnacipran.Approved
ChlorpromazineThe serum concentration of Levomilnacipran can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Levomilnacipran can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Levomilnacipran can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneLevomilnacipran may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levomilnacipran.Approved
CholecalciferolThe metabolism of Levomilnacipran can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Levomilnacipran can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Levomilnacipran can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Levomilnacipran can be increased when it is combined with Cilazapril.Approved
CimetidineThe metabolism of Levomilnacipran can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Levomilnacipran can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levomilnacipran.Approved, Vet Approved
CiprofloxacinThe serum concentration of Levomilnacipran can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CirazolineLevomilnacipran may increase the tachycardic activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Levomilnacipran.Approved
ClarithromycinThe serum concentration of Levomilnacipran can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Levomilnacipran can be decreased when combined with Clemastine.Approved
ClenbuterolLevomilnacipran may increase the tachycardic activities of Clenbuterol.Approved, Vet Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Levomilnacipran.Approved
ClobazamThe metabolism of Levomilnacipran can be decreased when combined with Clobazam.Approved, Illicit
ClofazimineThe serum concentration of Levomilnacipran can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Levomilnacipran.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Levomilnacipran.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Levomilnacipran.Approved, Illicit
ClonidineLevomilnacipran may increase the tachycardic activities of Clonidine.Approved
ClopidogrelThe metabolism of Levomilnacipran can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levomilnacipran.Approved, Illicit
ClotrimazoleThe metabolism of Levomilnacipran can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Levomilnacipran.Approved
CobicistatThe serum concentration of Levomilnacipran can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Levomilnacipran can be decreased when combined with Cocaine.Approved, Illicit
CodeineCodeine may increase the serotonergic activities of Levomilnacipran.Approved, Illicit
ColchicineThe serum concentration of Levomilnacipran can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Levomilnacipran can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Levomilnacipran can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Levomilnacipran can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Levomilnacipran.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levomilnacipran.Approved
CyclophosphamideThe serum concentration of Levomilnacipran can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Levomilnacipran can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe therapeutic efficacy of Levomilnacipran can be decreased when used in combination with Cyproheptadine.Approved
DabrafenibThe serum concentration of Levomilnacipran can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Levomilnacipran can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Levomilnacipran can be increased when it is combined with Dactinomycin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Levomilnacipran.Approved
DapagliflozinLevomilnacipran may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Levomilnacipran.Investigational
DarifenacinThe metabolism of Levomilnacipran can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Levomilnacipran can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Levomilnacipran can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Levomilnacipran can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Levomilnacipran can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Levomilnacipran can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Levomilnacipran.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Levomilnacipran.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Levomilnacipran.Approved
DesloratadineThe serum concentration of Levomilnacipran can be increased when it is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Levomilnacipran.Approved
DetomidineLevomilnacipran may increase the tachycardic activities of Detomidine.Vet Approved
DexamethasoneThe serum concentration of Levomilnacipran can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levomilnacipran.Approved
DexmedetomidineLevomilnacipran may increase the tachycardic activities of Dexmedetomidine.Approved, Vet Approved
DextromethorphanLevomilnacipran may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Levomilnacipran.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Levomilnacipran.Approved, Illicit, Withdrawn
DezocineDezocine may increase the serotonergic activities of Levomilnacipran.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Levomilnacipran.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Levomilnacipran can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Dicoumarol.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Levomilnacipran.Approved, Illicit
DigoxinThe serum concentration of Levomilnacipran can be decreased when it is combined with Digoxin.Approved
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Levomilnacipran.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Levomilnacipran.Approved
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Levomilnacipran.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Levomilnacipran.Experimental, Illicit
DiltiazemThe metabolism of Levomilnacipran can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levomilnacipran.Approved
DiphenhydramineThe metabolism of Levomilnacipran can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Levomilnacipran.Approved, Illicit
DipivefrinLevomilnacipran may increase the tachycardic activities of Dipivefrin.Approved
DipyridamoleThe serum concentration of Levomilnacipran can be increased when it is combined with Dipyridamole.Approved
DisopyramideLevomilnacipran may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineLevomilnacipran may increase the tachycardic activities of Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Levomilnacipran.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Levomilnacipran.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Levomilnacipran.Approved
DoxazosinThe serum concentration of Levomilnacipran can be increased when it is combined with Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Levomilnacipran.Approved
DoxorubicinThe serum concentration of Levomilnacipran can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Levomilnacipran can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Levomilnacipran.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Levomilnacipran.Investigational
DronabinolThe serum concentration of Levomilnacipran can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Levomilnacipran can be decreased when combined with Dronedarone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Droperidol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Levomilnacipran.Experimental, Illicit
DroxidopaLevomilnacipran may increase the tachycardic activities of Droxidopa.Approved, Investigational
DulaglutideLevomilnacipran may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Levomilnacipran.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levomilnacipran.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Levomilnacipran.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Levomilnacipran.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Levomilnacipran can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Levomilnacipran can be increased when it is combined with Elbasvir.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Levomilnacipran.Approved, Investigational
EliglustatThe metabolism of Levomilnacipran can be decreased when combined with Eliglustat.Approved
EmpagliflozinLevomilnacipran may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe serum concentration of Levomilnacipran can be increased when it is combined with Enalapril.Approved, Vet Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Levomilnacipran.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Levomilnacipran.Approved, Investigational
EnzalutamideThe serum concentration of Levomilnacipran can be decreased when it is combined with Enzalutamide.Approved
EphedraLevomilnacipran may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineLevomilnacipran may increase the tachycardic activities of Ephedrine.Approved
EpinephrineLevomilnacipran may increase the tachycardic activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Levomilnacipran.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Levomilnacipran.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Levomilnacipran.Approved
ErythromycinThe metabolism of Levomilnacipran can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Levomilnacipran.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Levomilnacipran can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe serum concentration of Esmolol can be increased when it is combined with Levomilnacipran.Approved
EsomeprazoleThe metabolism of Levomilnacipran can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Levomilnacipran.Approved, Illicit
EstramustineThe serum concentration of Levomilnacipran can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Levomilnacipran can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Levomilnacipran can be decreased when it is combined with Estrone.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levomilnacipran.Approved
EthanolEthanol can cause an increase in the absorption of Levomilnacipran resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levomilnacipran.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levomilnacipran.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levomilnacipran.Approved
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levomilnacipran.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Levomilnacipran.Approved, Illicit
EthylmorphineEthylmorphine may increase the serotonergic activities of Levomilnacipran.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Levomilnacipran.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Levomilnacipran.Withdrawn
EtilefrineLevomilnacipran may increase the tachycardic activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Levomilnacipran.Approved
EtodolacLevomilnacipran may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateLevomilnacipran may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneLevomilnacipran may increase the serotonergic activities of Etoperidone.Approved
EtoposideThe serum concentration of Levomilnacipran can be increased when it is combined with Etoposide.Approved
EtoricoxibLevomilnacipran may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Levomilnacipran.Illicit, Vet Approved
EtravirineThe serum concentration of Levomilnacipran can be decreased when it is combined with Etravirine.Approved
ExenatideLevomilnacipran may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Levomilnacipran.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Levomilnacipran.Approved
FelodipineThe serum concentration of Levomilnacipran can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineLevomilnacipran may increase the serotonergic activities of Fenfluramine.Illicit, Withdrawn
FenoterolLevomilnacipran may increase the tachycardic activities of Fenoterol.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levomilnacipran.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Levomilnacipran can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Levomilnacipran can be increased when it is combined with Fidaxomicin.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Levomilnacipran.Approved
FluconazoleThe metabolism of Levomilnacipran can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Levomilnacipran.Approved, Illicit
FluindioneThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Levomilnacipran.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Levomilnacipran.Approved, Illicit
FluoxetineThe metabolism of Levomilnacipran can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Levomilnacipran can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Levomilnacipran can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Levomilnacipran can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Levomilnacipran.Approved
FluvoxamineThe metabolism of Levomilnacipran can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolLevomilnacipran may increase the tachycardic activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Levomilnacipran can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Levomilnacipran can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Levomilnacipran can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Levomilnacipran.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Levomilnacipran.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Levomilnacipran.Approved, Vet Approved
Fusidic AcidThe serum concentration of Levomilnacipran can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levomilnacipran.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Levomilnacipran.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Levomilnacipran.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Levomilnacipran.Approved, Illicit
GefitinibThe serum concentration of Levomilnacipran can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe metabolism of Levomilnacipran can be decreased when combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Levomilnacipran can be increased when it is combined with Genistein.Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Levomilnacipran.Investigational
GliclazideLevomilnacipran may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideLevomilnacipran may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideLevomilnacipran may increase the hypoglycemic activities of Glipizide.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Levomilnacipran.Approved, Illicit
GlyburideThe serum concentration of Levomilnacipran can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Levomilnacipran can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Levomilnacipran can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the serotonergic activities of Levomilnacipran.Approved, Investigational
GrepafloxacinThe serum concentration of Levomilnacipran can be increased when it is combined with Grepafloxacin.Withdrawn
GuanabenzLevomilnacipran may increase the tachycardic activities of Guanabenz.Approved
GuanfacineLevomilnacipran may increase the tachycardic activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Levomilnacipran.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Levomilnacipran can be increased when it is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Levomilnacipran.Approved, Vet Approved
HeroinHeroin may increase the serotonergic activities of Levomilnacipran.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Levomilnacipran.Approved
HexoprenalineLevomilnacipran may increase the tachycardic activities of Hexoprenaline.Approved, Withdrawn
HigenamineLevomilnacipran may increase the tachycardic activities of Higenamine.Investigational
HydracarbazineHydracarbazine may increase the serotonergic activities of Levomilnacipran.Approved
HydrochlorothiazideLevomilnacipran may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneHydrocodone may increase the serotonergic activities of Levomilnacipran.Approved, Illicit
HydrocortisoneThe serum concentration of Levomilnacipran can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideLevomilnacipran may increase the hyponatremic activities of Hydroflumethiazide.Approved
HydromorphoneHydromorphone may increase the serotonergic activities of Levomilnacipran.Approved, Illicit
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Levomilnacipran.Approved
IdelalisibThe serum concentration of Levomilnacipran can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Iloperidone.Approved
ImatinibThe metabolism of Levomilnacipran can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Levomilnacipran.Approved
IndalpineLevomilnacipran may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideLevomilnacipran may increase the hyponatremic activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Levomilnacipran.Withdrawn
IndinavirThe serum concentration of Levomilnacipran can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Levomilnacipran can be increased when it is combined with Indomethacin.Approved, Investigational
Insulin AspartLevomilnacipran may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirLevomilnacipran may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineLevomilnacipran may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineLevomilnacipran may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanLevomilnacipran may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproLevomilnacipran may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Levomilnacipran.Approved
Ioflupane I-123Levomilnacipran may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideIproclozide may increase the serotonergic activities of Levomilnacipran.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Levomilnacipran.Withdrawn
IrbesartanThe metabolism of Levomilnacipran can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Levomilnacipran can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Levomilnacipran.Approved
IsoetarineLevomilnacipran may increase the tachycardic activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Levomilnacipran.Approved, Vet Approved
IsoniazidThe metabolism of Levomilnacipran can be decreased when combined with Isoniazid.Approved
IsoprenalineLevomilnacipran may increase the tachycardic activities of Isoprenaline.Approved
IsoxsuprineLevomilnacipran may increase the tachycardic activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Levomilnacipran can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Levomilnacipran can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Levomilnacipran can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Levomilnacipran can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Levomilnacipran.Approved
KetobemidoneKetobemidone may increase the serotonergic activities of Levomilnacipran.Approved
KetoconazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Levomilnacipran.Approved, Nutraceutical
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Levomilnacipran.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levomilnacipran.Approved, Investigational
LanreotideLevomilnacipran may increase the hypoglycemic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Levomilnacipran can be increased when it is combined with Lapatinib.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Levomilnacipran.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Levomilnacipran.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Levomilnacipran.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Levomilnacipran.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Levomilnacipran.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Levomilnacipran.Approved
LevofloxacinThe serum concentration of Levomilnacipran can be increased when it is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Levomilnacipran.Approved
LevothyroxineThe serum concentration of Levomilnacipran can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Levomilnacipran can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic activities of Levomilnacipran.Approved, Investigational
LiothyronineThe serum concentration of Levomilnacipran can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Levomilnacipran can be decreased when it is combined with Liotrix.Approved
LiraglutideLevomilnacipran may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe serum concentration of Levomilnacipran can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the serotonergic activities of Levomilnacipran.Approved
LofentanilLofentanil may increase the serotonergic activities of Levomilnacipran.Illicit
LofexidineLevomilnacipran may increase the tachycardic activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Levomilnacipran can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Levomilnacipran can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Levomilnacipran can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Levomilnacipran can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levomilnacipran.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Levomilnacipran.Approved
LosartanThe serum concentration of Levomilnacipran can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Levomilnacipran can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Loxapine.Approved
Lu AA21004Levomilnacipran may increase the serotonergic activities of Lu AA21004.Investigational
LuliconazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Levomilnacipran can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Levomilnacipran can be decreased when combined with Lumefantrine.Approved
LumiracoxibLevomilnacipran may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Lurasidone.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Levomilnacipran.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levomilnacipran.Approved
MebanazineMebanazine may increase the serotonergic activities of Levomilnacipran.Withdrawn
MebendazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecaserminLevomilnacipran may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Levomilnacipran.Approved
MedetomidineLevomilnacipran may increase the tachycardic activities of Medetomidine.Vet Approved
MefloquineThe serum concentration of Levomilnacipran can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Levomilnacipran can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Levomilnacipran.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Melperone.Approved
MephentermineLevomilnacipran may increase the tachycardic activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levomilnacipran.Approved, Vet Approved
MeprobamateThe serum concentration of Levomilnacipran can be increased when it is combined with Meprobamate.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levomilnacipran.Approved
MetaraminolLevomilnacipran may increase the tachycardic activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levomilnacipran.Approved
MetforminLevomilnacipran may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Levomilnacipran.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Levomilnacipran.Approved, Illicit
MethamphetamineLevomilnacipran may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Levomilnacipran.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Levomilnacipran.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levomilnacipran.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Levomilnacipran.Approved
MethotrimeprazineThe metabolism of Levomilnacipran can be decreased when combined with Methotrimeprazine.Approved
MethoxamineLevomilnacipran may increase the tachycardic activities of Methoxamine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levomilnacipran.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Levomilnacipran.Approved
MethyclothiazideLevomilnacipran may increase the hyponatremic activities of Methyclothiazide.Approved
MethyldopaLevomilnacipran may increase the tachycardic activities of Methyldopa.Approved
Methylene blueLevomilnacipran may increase the serotonergic activities of Methylene blue.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levomilnacipran.Approved
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Levomilnacipran.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Levomilnacipran.Approved, Investigational
MetolazoneLevomilnacipran may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Levomilnacipran can be increased when it is combined with Metoprolol.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Levomilnacipran.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Levomilnacipran.Approved
MibefradilThe serum concentration of Levomilnacipran can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Levomilnacipran can be decreased when it is combined with Midazolam.Approved, Illicit
MidodrineLevomilnacipran may increase the tachycardic activities of Midodrine.Approved
MifepristoneThe serum concentration of Levomilnacipran can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolLevomilnacipran may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Levomilnacipran.Approved
MinaprineMinaprine may increase the serotonergic activities of Levomilnacipran.Approved
MirabegronLevomilnacipran may increase the tachycardic activities of Mirabegron.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Levomilnacipran.Approved
MitomycinThe serum concentration of Levomilnacipran can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Levomilnacipran can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Levomilnacipran can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideMoclobemide may increase the serotonergic activities of Levomilnacipran.Approved
ModafinilThe serum concentration of Levomilnacipran can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Molindone.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Levomilnacipran.Approved, Withdrawn
MorphineThe serum concentration of Levomilnacipran can be increased when it is combined with Morphine.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Levomilnacipran.Approved, Investigational
NabumetoneLevomilnacipran may increase the antiplatelet activities of Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Levomilnacipran.Approved
NafcillinThe serum concentration of Levomilnacipran can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Levomilnacipran.Approved
NaltrexoneThe serum concentration of Levomilnacipran can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaphazolineLevomilnacipran may increase the tachycardic activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Levomilnacipran.Approved, Investigational
NaringeninThe serum concentration of Levomilnacipran can be increased when it is combined with Naringenin.Experimental
NateglinideLevomilnacipran may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololLevomilnacipran may increase the tachycardic activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Levomilnacipran can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Levomilnacipran can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Levomilnacipran can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Levomilnacipran can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Levomilnacipran can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Levomilnacipran.Withdrawn
NicardipineThe serum concentration of Levomilnacipran can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Levomilnacipran can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Levomilnacipran can be decreased when combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Levomilnacipran can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Levomilnacipran can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Levomilnacipran can be increased when it is combined with Nitrendipine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Levomilnacipran.Approved, Vet Approved
NorepinephrineLevomilnacipran may increase the tachycardic activities of Norepinephrine.Approved
NorethisteroneThe serum concentration of Levomilnacipran can be decreased when it is combined with Norethisterone.Approved
NormethadoneNormethadone may increase the serotonergic activities of Levomilnacipran.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Levomilnacipran.Approved
NylidrinLevomilnacipran may increase the tachycardic activities of Nylidrin.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Levomilnacipran.Withdrawn
OctreotideLevomilnacipran may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OlanzapineLevomilnacipran may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlaparibThe metabolism of Levomilnacipran can be decreased when combined with Olaparib.Approved
OlodaterolLevomilnacipran may increase the tachycardic activities of Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levomilnacipran.Approved
OmeprazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the serotonergic activities of Levomilnacipran.Approved
OpiumOpium may increase the serotonergic activities of Levomilnacipran.Approved, Illicit
OrciprenalineLevomilnacipran may increase the tachycardic activities of Orciprenaline.Approved
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Levomilnacipran.Approved
OsanetantThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Levomilnacipran can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levomilnacipran.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Oxetacaine is combined with Levomilnacipran.Investigational
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Levomilnacipran.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Levomilnacipran.Approved
OxycodoneOxycodone may increase the serotonergic activities of Levomilnacipran.Approved, Illicit, Investigational
OxymetazolineLevomilnacipran may increase the tachycardic activities of Oxymetazoline.Approved
OxymorphoneOxymorphone may increase the serotonergic activities of Levomilnacipran.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Levomilnacipran can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Levomilnacipran can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Levomilnacipran can be increased when it is combined with Palbociclib.Approved
PaliperidoneLevomilnacipran may decrease the antihypertensive activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Levomilnacipran can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronPalonosetron may increase the serotonergic activities of Levomilnacipran.Approved, Investigational
PanobinostatThe serum concentration of Levomilnacipran can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Pantoprazole.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Levomilnacipran.Approved
ParecoxibLevomilnacipran may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Levomilnacipran.Approved
ParoxetineThe metabolism of Levomilnacipran can be decreased when combined with Paroxetine.Approved, Investigational
PasireotideLevomilnacipran may increase the hypoglycemic activities of Pasireotide.Approved
Peginterferon alfa-2bThe serum concentration of Levomilnacipran can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Levomilnacipran.Approved, Investigational
PentamidineLevomilnacipran may increase the hypoglycemic activities of Pentamidine.Approved
PentazocinePentazocine may increase the serotonergic activities of Levomilnacipran.Approved, Vet Approved
PentobarbitalThe metabolism of Levomilnacipran can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Levomilnacipran.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Levomilnacipran.Investigational
PergolideLevomilnacipran may decrease the antihypertensive activities of Pergolide.Approved, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Levomilnacipran can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levomilnacipran.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Levomilnacipran.Approved
PhenelzinePhenelzine may increase the serotonergic activities of Levomilnacipran.Approved
PhenindioneThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Phenindione.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Levomilnacipran.Withdrawn
PhenobarbitalThe metabolism of Levomilnacipran can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Levomilnacipran.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Levomilnacipran.Withdrawn
PhenprocoumonThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Phenprocoumon.Approved
PhenylephrineLevomilnacipran may increase the tachycardic activities of Phenylephrine.Approved
PhenylpropanolamineLevomilnacipran may increase the tachycardic activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Levomilnacipran can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Pimozide.Approved
PindololThe serum concentration of Pindolol can be increased when it is combined with Levomilnacipran.Approved
PioglitazoneLevomilnacipran may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Pipotiazine.Approved
PirbuterolLevomilnacipran may increase the tachycardic activities of Pirbuterol.Approved
PiritramidePiritramide may increase the serotonergic activities of Levomilnacipran.Investigational
PirlindolePirlindole may increase the serotonergic activities of Levomilnacipran.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Levomilnacipran.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Levomilnacipran.Approved
Platelet Activating FactorThe serum concentration of Levomilnacipran can be decreased when it is combined with Platelet Activating Factor.Experimental
PolythiazideLevomilnacipran may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Levomilnacipran.Approved
PonatinibThe serum concentration of Levomilnacipran can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Levomilnacipran.Approved
PramlintideLevomilnacipran may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Levomilnacipran.Approved
PravastatinThe serum concentration of Levomilnacipran can be increased when it is combined with Pravastatin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Levomilnacipran.Approved, Illicit
PrazosinThe serum concentration of Levomilnacipran can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Levomilnacipran can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Levomilnacipran.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Pregnanolone is combined with Levomilnacipran.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Levomilnacipran.Approved
PrimidoneThe metabolism of Levomilnacipran can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Levomilnacipran can be increased when it is combined with Probenecid.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Levomilnacipran.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Levomilnacipran.Approved
ProcaterolLevomilnacipran may increase the tachycardic activities of Procaterol.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levomilnacipran.Approved, Vet Approved
ProgesteroneThe serum concentration of Levomilnacipran can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe metabolism of Levomilnacipran can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Levomilnacipran.Approved
PropafenoneThe serum concentration of Levomilnacipran can be increased when it is combined with Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levomilnacipran.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Propericiazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Levomilnacipran.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Levomilnacipran.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Levomilnacipran.Approved
PropranololThe serum concentration of Levomilnacipran can be increased when it is combined with Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levomilnacipran.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Levomilnacipran.Investigational
PseudoephedrineLevomilnacipran may increase the tachycardic activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Levomilnacipran.Approved, Illicit
QuercetinThe serum concentration of Levomilnacipran can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Levomilnacipran can be increased when it is combined with Quinacrine.Approved
QuinethazoneLevomilnacipran may increase the hyponatremic activities of Quinethazone.Approved
QuinidineThe metabolism of Levomilnacipran can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Levomilnacipran can be increased when it is combined with Quinine.Approved
RabeprazoleThe metabolism of Levomilnacipran can be decreased when combined with Rabeprazole.Approved, Investigational
RacepinephrineLevomilnacipran may increase the tachycardic activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Raclopride.Investigational
RactopamineLevomilnacipran may increase the tachycardic activities of Ractopamine.Vet Approved
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Levomilnacipran.Approved, Investigational
RanitidineThe serum concentration of Levomilnacipran can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Levomilnacipran can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Levomilnacipran.Approved
ReboxetineThe serum concentration of Levomilnacipran can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Levomilnacipran can be increased when it is combined with Regorafenib.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Levomilnacipran.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Remoxipride.Approved, Withdrawn
RepaglinideLevomilnacipran may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReserpineThe serum concentration of Levomilnacipran can be decreased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Levomilnacipran can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Levomilnacipran can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Levomilnacipran can be increased when combined with Rifapentine.Approved
RilmenidineLevomilnacipran may increase the tachycardic activities of Rilmenidine.Investigational
RilpivirineThe serum concentration of Levomilnacipran can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Levomilnacipran.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Ritanserin.Investigational
RitobegronLevomilnacipran may increase the tachycardic activities of Ritobegron.Investigational
RitodrineLevomilnacipran may increase the tachycardic activities of Ritodrine.Approved
RitonavirThe serum concentration of Levomilnacipran can be increased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Levomilnacipran.Approved
RofecoxibLevomilnacipran may increase the antiplatelet activities of Rofecoxib.Investigational, Withdrawn
RolapitantThe serum concentration of Levomilnacipran can be increased when it is combined with Rolapitant.Approved
RomifidineLevomilnacipran may increase the tachycardic activities of Romifidine.Vet Approved
RopiniroleThe metabolism of Levomilnacipran can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levomilnacipran.Approved
RosiglitazoneLevomilnacipran may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Levomilnacipran.Experimental
SafrazineSafrazine may increase the serotonergic activities of Levomilnacipran.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Sage 547 is combined with Levomilnacipran.Investigational
SalbutamolLevomilnacipran may increase the tachycardic activities of Salbutamol.Approved, Vet Approved
SalmeterolLevomilnacipran may increase the tachycardic activities of Salmeterol.Approved
SaquinavirThe serum concentration of Levomilnacipran can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinLevomilnacipran may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe serum concentration of Levomilnacipran can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Levomilnacipran can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Levomilnacipran.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Levomilnacipran.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Levomilnacipran.Approved, Vet Approved
SildenafilThe metabolism of Levomilnacipran can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Levomilnacipran can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Levomilnacipran can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Levomilnacipran can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Levomilnacipran can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinLevomilnacipran may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Levomilnacipran.Approved
SolabegronLevomilnacipran may increase the tachycardic activities of Solabegron.Investigational
SorafenibThe serum concentration of Levomilnacipran can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolThe serum concentration of Sotalol can be increased when it is combined with Levomilnacipran.Approved
SpironolactoneThe serum concentration of Levomilnacipran can be increased when it is combined with Spironolactone.Approved
SR 58611Levomilnacipran may increase the tachycardic activities of SR 58611.Investigational
St. John's WortThe serum concentration of Levomilnacipran can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Levomilnacipran can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Levomilnacipran can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Levomilnacipran can be decreased when it is combined with Streptozocin.Approved
SufentanilSufentanil may increase the serotonergic activities of Levomilnacipran.Approved, Investigational
SulfadiazineLevomilnacipran may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleLevomilnacipran may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Levomilnacipran can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Levomilnacipran can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Levomilnacipran.Approved, Investigational
SunitinibThe serum concentration of Levomilnacipran can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Levomilnacipran.Approved
SynephrineLevomilnacipran may increase the tachycardic activities of Synephrine.Experimental
TacrineThe serum concentration of Levomilnacipran can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Levomilnacipran.Approved, Investigational
TacrolimusThe serum concentration of Levomilnacipran can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Levomilnacipran can be decreased when it is combined with Tamoxifen.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Levomilnacipran.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Levomilnacipran.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Levomilnacipran.Approved
Taurocholic AcidThe serum concentration of Levomilnacipran can be increased when it is combined with Taurocholic Acid.Experimental
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Levomilnacipran.Approved
TelaprevirThe serum concentration of Levomilnacipran can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Levomilnacipran can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Levomilnacipran can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Levomilnacipran.Approved
TemsirolimusThe serum concentration of Levomilnacipran can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Levomilnacipran can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Levomilnacipran can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineLevomilnacipran may increase the tachycardic activities of Terbutaline.Approved
TerfenadineThe serum concentration of Levomilnacipran can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe metabolism of Levomilnacipran can be decreased when combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Levomilnacipran can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Levomilnacipran can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Levomilnacipran.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Levomilnacipran.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Levomilnacipran.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Levomilnacipran.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levomilnacipran.Approved, Vet Approved
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Levomilnacipran.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Levomilnacipran.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Thioproperazine.Approved
ThioridazineThe metabolism of Levomilnacipran can be decreased when combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Thiothixene.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Levomilnacipran.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Levomilnacipran.Approved
TiaprideThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Levomilnacipran can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Levomilnacipran can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Levomilnacipran.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Levomilnacipran.Approved
TipranavirThe metabolism of Levomilnacipran can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineLevomilnacipran may increase the tachycardic activities of Tizanidine.Approved
TocilizumabThe serum concentration of Levomilnacipran can be decreased when it is combined with Tocilizumab.Approved
TolazamideLevomilnacipran may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideLevomilnacipran may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levomilnacipran.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Levomilnacipran.Approved
TolvaptanThe serum concentration of Levomilnacipran can be increased when it is combined with Tolvaptan.Approved
TopiramateThe metabolism of Levomilnacipran can be decreased when combined with Topiramate.Approved
TramadolLevomilnacipran may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Levomilnacipran.Experimental
TranylcypromineTranylcypromine may increase the serotonergic activities of Levomilnacipran.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Levomilnacipran.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Levomilnacipran.Approved
TrichlormethiazideLevomilnacipran may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Levomilnacipran can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Levomilnacipran can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Levomilnacipran can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levomilnacipran.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Levomilnacipran.Approved
TroleandomycinThe serum concentration of Levomilnacipran can be increased when it is combined with Troleandomycin.Approved
TropisetronTropisetron may increase the serotonergic activities of Levomilnacipran.Investigational
TulobuterolLevomilnacipran may increase the tachycardic activities of Tulobuterol.Investigational
Uc1010The risk or severity of adverse effects can be increased when Uc1010 is combined with Levomilnacipran.Investigational
ValdecoxibLevomilnacipran may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Levomilnacipran.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Levomilnacipran.Approved
VerapamilThe metabolism of Levomilnacipran can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Levomilnacipran.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Levomilnacipran.Approved
VinblastineThe serum concentration of Levomilnacipran can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Levomilnacipran can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Levomilnacipran can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe serum concentration of Levomilnacipran can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Vortioxetine.Approved
WarfarinThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Warfarin.Approved
XylazineLevomilnacipran may increase the tachycardic activities of Xylazine.Vet Approved
XylometazolineLevomilnacipran may decrease the antihypertensive activities of Xylometazoline.Approved
YM-178Levomilnacipran may increase the tachycardic activities of YM-178.Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levomilnacipran.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Levomilnacipran.Approved
ZimelidineLevomilnacipran may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Levomilnacipran can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Levomilnacipran.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Levomilnacipran.Approved, Investigational
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Levomilnacipran.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levomilnacipran.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Levomilnacipran.Approved
ZotepineThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS Codes
  • 28:16.04.16
PDB EntriesNot Available
FDA labelDownload (530 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9889
Caco-2 permeable+0.5914
P-glycoprotein substrateSubstrate0.5928
P-glycoprotein inhibitor INon-inhibitor0.902
P-glycoprotein inhibitor IINon-inhibitor0.8787
Renal organic cation transporterNon-inhibitor0.8119
CYP450 2C9 substrateNon-substrate0.8494
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6514
CYP450 1A2 substrateNon-inhibitor0.6383
CYP450 2C9 inhibitorNon-inhibitor0.7697
CYP450 2D6 inhibitorNon-inhibitor0.7718
CYP450 2C19 inhibitorNon-inhibitor0.8587
CYP450 3A4 inhibitorNon-inhibitor0.6327
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7004
Ames testNon AMES toxic0.8013
CarcinogenicityNon-carcinogens0.5456
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.6162 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.993
hERG inhibition (predictor II)Non-inhibitor0.6823
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsule, extended releaseOral120 mg/1
Capsule, extended releaseOral120 mg
Capsule, extended releaseOral20 mg/1
Capsule, extended releaseOral20 mg
Capsule, extended releaseOral40 mg/1
Capsule, extended releaseOral40 mg
Capsule, extended releaseOral80 mg
Capsule, extended releaseOral80 mg/1
KitOral
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8481598 No2011-03-022031-03-02Us
US8865937 No2012-05-232032-05-23Us
USRE43879 No2003-06-032023-06-03Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
logP1.42ChemAxon
pKa (Strongest Basic)9.83ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.33 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity73.81 m3·mol-1ChemAxon
Polarizability28.33 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylacetamides. These are amide derivatives of phenylacetic acids.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylacetamides
Direct ParentPhenylacetamides
Alternative Parents
Substituents
  • Phenylacetamide
  • Aralkylamine
  • Cyclopropanecarboxylic acid or derivatives
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Carboxamide group
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
This enzyme metabolizes arachidonic acid predominantly via a NADPH-dependent olefin epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids. One of the predominant enzymes responsible for the epoxidation of endogenous cardiac arachidonic acid pools.
Gene Name:
CYP2J2
Uniprot ID:
P51589
Molecular Weight:
57610.165 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Comments
comments powered by Disqus
Drug created on August 01, 2013 14:17 / Updated on December 07, 2016 02:40